Discovery of Dangerous Drugs Containing Designated Substances
Overview
The Ministry of Health, Labour and Welfare reported that it had received notification from the Tokyo Metropolitan Government at 2:00 p.m. today that Tokyo had held a press conference, as shown in the attachment, concerning the discovery of dangerous drugs containing designated substances. The announcement is provided in the attached PDF. Inquiries should be directed to the Pharmaceutical Surveillance and Narcotics Control Division of the Pharmaceutical Safety Bureau. The article does not specify the names, ingredients, quantities, or response measures concerning the dangerous drugs discovered.
Key points
- The Ministry of Health, Labour and Welfare reported that it had received notification from the Tokyo Metropolitan Government concerning a press conference about the discovery of dangerous drugs containing designated substances.
- The Tokyo Metropolitan Government notified the ministry that it had held a press conference, and the notification was made at 2:00 p.m. today.
- The details are provided in the attached PDF material.
Overview
This material, issued as a press release by the Ministry of Health, Labour and Welfare, reports that the ministry had received notification from the Tokyo Metropolitan Government concerning a press conference about the discovery of dangerous drugs containing designated substances. It reports the contents of the notification that Tokyo had held a press conference, as shown in the attachment.
Based on what can be confirmed in the article, the focus is on the existence of an announcement concerning the discovery of dangerous drugs and guidance to the relevant material; specific information about the drugs discovered and subsequent measures are not described in the article.
Details
The time of the notification from the Tokyo Metropolitan Government was 2:00 p.m. today, and does not indicate the time at which the press conference was held. The date of the material is September 10, 2026 (Thursday).
The detailed material is provided as an attachment titled Discovery of Dangerous Drugs Containing Designated Substances [PDF format: 4.0MB]. The article itself does not include the contents of the PDF.
Inquiries should be directed to the Pharmaceutical Surveillance and Narcotics Control Division. Yuhei Nishimura is listed as Deputy Section Chief, and Koya Mori as Senior Specialist. The main telephone number is 03-5253-1111, and the direct telephone number is 03-3595-2436.